Drug: Afatinib Dimaleate to Treat NSCLC

Afatinib DimaleateTreatment of Lung Cancer

Lung cancer is a type of cancer that starts in lungs and those who smoke have a higher risk of having this disease. The best way smokers can reduce their probability of having lung cancer is by quitting smoking. For effective lung cancer medication, Afatinib Dimaleate is used. Afatinib dimaleate is approved for the treatment of non-small cell lung cancer. It is used as a first-line lung cancer treatment among patients with tumors. It is used to treat NSCLC that has spread to other parts of the body as well. It may also help keep cancer cells from growing.

How Afatinib Dimaleate works?

The drug works by slowing or stopping the growth of cancer cells. It works to bind to a certain protein in tumors. It may stop the growth of tumor cells by blocking some enzymes which are required for cell growth. In addition, it may work to prevent the growth of new blood vessels that tumors need for growing. Thus, it helps to stop cancer cells from spreading. Afatinib Dimaleate is a low-cost option for treatment of lung cancer and is also very effective in treating the disease.

Dosage

The dosage of the drug depends on the medical condition, response to treatment and other medications you are having. You should tell your health practitioner about all medications including prescribed drugs, non-prescribed drugs and herbal medicines you take. Generally, the drug is taken at least one hour before the meal or two hours after the meal. You should not increase your dose or use this drug more than prescribed.

Side Effects

Diarrhea is a common side effect of this drug. Women who are pregnant or who are breastfeeding should not take this medication. Before you receive any medical treatment, let your health professional know that you are using it.

What are your thoughts about lung cancer treatment? Let us know in the comments.

 

All the information offered in this blog is for educational purposes. It is certainly not a substitute for medical advice.

Leave a Reply